Probabilistic steering improves antibody design efficiency and diversity
Probabilistic Steering of Generative Priors for Lab-in-the-Loop Antibody Optimization
Machine Learning
Summary
Developing therapeutic antibodies often involves two separate steps: first finding new candidates and then improving them in the lab. The authors show how combining computer models that generate new antibody structures with lab data in a smooth way can make this process more efficient. Their method uses uncertainty in the model’s predictions to decide how much to trust computer-generated ideas versus real lab results. This approach helps find better and more varied antibodies especially when only a small amount of lab data is available.
What this means in practice
- •For biotechnology developers: Optimize antibody candidates more efficiently using probabilistic guidance that balances computer models and experimental data.$Commercial implications: Supports development of faster and cost-effective antibody therapies by improving computational-lab integration in the design pipeline.
- •For protein engineering teams: Increase diversity of optimized protein designs by using uncertainty-aware generative models to guide iterative improvement.
Authors
Anisha Parsan, Sebastian Ober, Calvin McCarter, Nick Bhattacharya, Hunter Elliott
Abstract
Therapeutic antibody development is often framed as comprising two discrete stages: initial discovery of novel binders followed by iterative optimization to refine these hits into therapeutic-grade molecules. Models and methods often reflect these stages, with generative structure models applied to discovery and probabilistic black-box optimization methods applied to refinement. Here we propose to unify these stages by smoothly transitioning a generative discovery model into iterative optimization, allowing the handoff between the structure-based prior and supervision from wet lab data to be guided by the posterior uncertainty of a probabilistic surrogate. We show that this yields improvements in optimization efficiency in the low-N regime, as well as improved diversity amongst the optimized molecules.